SCHEMBL2410862

SCHEMBL2410862

CCCCCCCN(CCc1csc(SC(C)(C)C(=O)O)n1)c1cccc(C#N)c1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 4/20 0.41
▸ PPARG P37231 3/20 0.40
▸ SLC22A12 Q96S37 4/20 0.38
▸ ALOX15 P16050 1/20 0.37
▸ PPARD Q03181 2/20 0.37
▸ KCNN4 O15554 1/20 0.35
▸ KCNA5 P22460 1/20 0.35
▸ P4HB P07237 1/20 0.35
▸ PTPN11 Q06124 1/20 0.33
▸ PTPRO Q16827 1/20 0.33
▸ SLC16A3 O15427 1/20 0.33
▸ SLC16A1 P53985 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2412574 0.90 PPARA (0.42) PPARAPPARGSLC22A12PPARDPTPN11
SCHEMBL2415854 0.87 PPARA (0.36) PPARAPPARGSLC22A12PPARDSLC16A3
SCHEMBL12274371 0.86 PPARA (0.41) PPARAPPARGSLC22A12ALOX15PPARD
SCHEMBL2416659 0.86 PPARA (0.43) PPARAPPARGSLC22A12ALOX15PPARD
Hydrochloric Acid SCHEMBL2414406 0.86 PPARA (0.41) PPARAPPARGSLC22A12ALOX15PPARD
SCHEMBL2414917 0.85 SLC22A12 (0.39) PPARAPPARGSLC22A12PPARDSLC16A3
SCHEMBL12274123 0.85 PPARA (0.35) PPARAPPARGPPARD
SCHEMBL12320108 0.84 PPARA (0.40) PPARAPPARGSLC22A12PPARD
SCHEMBL2413853 0.83 PPARA (0.35) PPARAPPARGSLC22A12PPARD
Trifluoroacetic Acid SCHEMBL2413776 0.83 PPARA (0.38) PPARAPPARGSLC22A12PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 — — US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 — — US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG PPARA 1/4885PPARG 3/4885SLC22A12 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback